Payment overview · 2025
General Payments
$239.62
12 reported records · 8 companies
Healthcare provider profile · identity verified
Mark H Bernhard, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT WORTH, TX · NPI 1912924515
Verified facts
What the public records show
CMS Open Payments records show Mark H Bernhard, MD received $239.62 in general payments during 2025 across 12 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.02 | 19.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.55 | 18.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.07 | 16.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.11 | 11.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.39 | 10.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.81 | 9.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.23 | 8.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.44 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $239.62 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.02 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.95 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
49 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 76 |
| Lisinopril | Lisinopril | 171 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 54 |
| Metformin Hcl | Metformin Hcl | 151 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 48 |
| Simvastatin | Simvastatin | 137 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 44 |
| Alendronate Sodium | Alendronate Sodium | 112 | 34 |
| Glimepiride | Glimepiride | 111 | 35 |
| Montelukast Sodium | Montelukast Sodium | 104 | 34 |
| Allopurinol | Allopurinol | 101 | 28 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 92 | 91 |
| Gabapentin | Gabapentin | 92 | 36 |
| Omeprazole | Omeprazole | 90 | 26 |
| Valsartan | Valsartan | 87 | 25 |
| Trazodone Hcl | Trazodone Hcl | 85 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 29 |
| Losartan Potassium | Losartan Potassium | 77 | 29 |
| Methylprednisolone | Methylprednisolone | 74 | 67 |
| Enalapril Maleate | Enalapril Maleate | 71 | 23 |
| Furosemide | Furosemide | 70 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 28 |
| Jardiance | Empagliflozin | 61 | 20 |
| Finasteride | Finasteride | 60 | 21 |
| Meloxicam | Meloxicam | 59 | 25 |
| Carvedilol | Carvedilol | 58 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Pregabalin | Pregabalin | 44 | 16 |
| Potassium Chloride | Potassium Chloride | 43 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 41 |
| Celecoxib | Celecoxib | 39 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 14 |
| Lorazepam | Lorazepam | 38 | 12 |
| Atenolol | Atenolol | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 14 |
| Alprazolam | Alprazolam | 36 | 19 |
| Chlorthalidone | Chlorthalidone | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 11 |
| Eliquis | Apixaban | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 21 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | 11 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $239.62 · 12 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, INCEPTIV, INSPIRE, JARDIANCE, KRYSTEXXA, Kerendia, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error